Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study.

Neurol Neuroimmunol Neuroinflamm · 2018 · PMC6047834 · PMID 30027104

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

All efficacy analyses were exploratory because the study was not powered to detect between-group differences for any end point, and all p values less than 0.05 are considered as nominally significant.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.